- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
This Week in Managed Care: June 11, 2016
This week in managed care, the top stories included discussions on biomarkers and financial toxicity at the annual meeting of the American Society of Clinical Oncology, and a preview of the 76th Scientific Sessions of the American Diabetes Association.
Hello, I’m Justin Gallagher, associate publisher of The American Journal of Managed Care. Welcome to This Week in Managed Care, from the Managed Markets News Network.
Biomarkers at ASCO
The challenges of finding useful biomarkers to identify which patients will respond to checkpoint inhibitors, and the many new combinations of immunotherapy took center stage at the recent meeting of the American Society of Clinical Oncology.
Scientists discussed the need for new biomarkers—which help prevent giving expensive therapy to the wrong patients. Their questions include:
- How can researchers increase the number of next-generation checkpoint inhibitors?
- How can they be used in combination with vaccines, radiation, and chemotherapy?
- Should biomarkers be investigated beyond the PD-L1 expression?
Financial Toxicity
In addition to clinical breakthroughs, more and more time at ASCO is spent on the cost of cancer care. Dr Veena Shankaran, author of a recent article in Evidence-Based Oncology, led a panel that discussed the challenges of financial toxicity for patients. She said, “Financial toxicity is a constellation of symptoms. Patients face difficulty meeting household expenses; they face financial stress and strain, loss of employment and income, debt and bankruptcy.”
Value frameworks in cancer care are getting a lot of attention. But are payers using them? Dr. Michael Kolodziej of Aetna says the frameworks are still missing key elements that he says payers will need to find them useful. Watch the interview.
ADA 2016
This weekend, 16,000 scientists, diabetes educators, patients, and advocates will gather in New Orleans for the 76th Scientific Sessions of the American Diabetes Association, which features a mix of clinical and technological developments.
Here are 5 things to look for at ADA:
- Results from 2 cardiovascular outcomes trials: the LEADER study for liraglutide and the EMPA-REG study of empagliflozin
- Technology updates, including progress toward the artificial pancreas
- A session with young investigators will report on a new drug target for type 2 diabetes
- Dr Frank Hu will discuss the controversy over the 2015 Dietary Guidelines
- Dr Robert Gabbay of Joslin Diabetes Center will chair a session on paying for diabetes care
Sign up for coverage that will appear June 11-13.
New Podcast
Finally, this week AJMC launched its first podcast: Managed Care Cast. Our first program features faculty from our recent conference, Patient-Centered Diabetes Care. Listen to the podcast.
For all of us at the Managed Markets News Network, I’m Justin Gallagher. Thanks for joining us.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
